



CLAIMS

1. A group of oligonucleotides specifically bind to human tumor necrosis factor α (TNF- α) selected from sequences showed in SEQ Nos. 1-28.

5 2. The oligonucleotide sequences as recited in Claim 1 including DNA sequences and RNA sequences, wherein the DNA SEQ No. 1-18 has one of the secondary structures as following:



15 3. The oligonucleotide sequences as recited in Claim 1, wherein the RNA SEQ
No. 19-28 sequence has one of the secondary structures as following:



25 4. The oligonucleotide sequences as recited in Claim 1 including a homologue
oligonucleotide sequence that has 70% homologue with and functions identical to the
oligonucleotide sequence.

5. The oligonucleotides sequence as recited in Claim 1 including a truncated
oligonucleotide sequence that functions identical to the oligonucleotide sequence.

6. The oligonucleotides sequences as recited in Claim 1 including a modified oligonucleotides sequence that functions identical to the oligonucleotides sequence.
7. A hybridizing oligonucleotides sequence which hybridize with the oligonucleotides sequence as recited in Claim 1 under strict condition.
- 5 8. A derivated oligonucleotide sequence from the oligonucleotides sequence as recited in Claim 1.
9. The application of the oligonucleotides sequence as recited in any one of Claims 1, 5, 6, and 7 for manufacture for therapy and diagnosis of TNF- α related diseases.

10